# First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine

> **NCT01188512** · PHASE1 · COMPLETED · sponsor: **Institut National de la Santé Et de la Recherche Médicale, France** · enrollment: 48 (actual)

## Conditions studied

- Pertussis

## Interventions

- **BIOLOGICAL:** BPZE1
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01188512
- **Lead sponsor:** Institut National de la Santé Et de la Recherche Médicale, France
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-06
- **Final completion:** 2012-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01188512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01188512, "First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01188512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*